drugset
drugset / Trial / NCT05151614

Adjuvant Use Of Colchicine With The Standard Therapy In Moderate And Severe Corona Virus Disease-19 Infection

NCT05151614 ↗

Phase 1 Completed 160 enrolled University of Baghdad
RandomizedParallel-groupOpen-labelTreatment

Summary

The study included 2 arms Colchicine group: Colchicine + standard therapy of COVID-19 Control group: Standard therapy of COVID-19

Timeline

Start
2021-04-01
Primary completion
2021-10-30
Completion
2021-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Colchicine Small molecule 0.5 mg —

Indications

COVID-19